SEC Form 4 · accession 0000899243-17-022443
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard L Love
Director
Period of report
Sep 20, 2017
Accepted (ET)
Sep 22, 2017 · 4:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $4.25 | Sep 20, 2017 | A | 50,000 | A | — | Sep 19, 2027 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1This stock option was granted on September 20, 2017 and vests on the first to occur of (i) the date that is twelve months after the date of grant, (ii) the first annual meeting of CTIC's shareholders in 2018 at which one or more members of the CTIC Board of Directors are to be elected, or (iii) immediately prior to the occurrence of a Change of Control (as such term is defined in CTIC's 2017 Equity Incentive Plan), subject to the Reporting Persons' continued service through such date or event.